



Piramal Phytocare

knowledge action care

13th February, 2015

Corporate Relationship Department,
BSE Limited
New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street, Fort,
Mumbai- 400 001

Fax No. 22723121/22721072
22722037

The Market Operations Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block
Bandra-Kurla Complex, Bandra (E)
Mumbai- 400 051

Fax No. 26598237
26598238

Dear Sir / Madam,

BSE Scrip Code : 532979
NSE Symbol : PIRPHYTO

Sub: Outcome of Board Meeting

Kindly refer to our letter dated 5th February, 2015 on the above subject.

At its meeting held today, the following decisions were taken by the Board of Directors:

1. Unaudited Financial Results

The Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2014 were approved by the Board of Directors. The Financial Highlights as per Clause 41 of the Listing Agreement are enclosed. The said results have been subjected to limited review by the Auditors of the Company and a copy of their Limited Review Report is enclosed.

2. Resignation of Chief Financial Officer (CFO)

Mr. Deepak Tipnis has tendered his resignation as the Chief Financial Officer (CFO) of the Company with effect from close of business hours on 13th February, 2015. The Company is in the process of appointing a new CFO.

Thanking you,

Yours truly,

For Piramal Phytocare Limited

Neelesh Bhise
Company Secretary

Encl: as above

Piramal Phytocare Limited

(formerly known as Piramal Life Sciences Limited)

CIN : L73100MH2001PLC132523

Regd. Office : Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

Secretarial Dept : Piramal Tower Annexe, 1st floor, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

T +91 22 3046 7953 / 7839 F +91 22 3046 7855

W www.pls-l.com

Haribhakti & Co.


CHARTERED ACCOUNTANTS

18, Haribhakti Colony, Race Course Circle, Vadodara-390 007.
Tel.: (O) 91-265-234 0091, Tele Fax : 91-265-231 4495, E-mail: misa@haribhaktica.com

To,
The Board of Directors,
Piramal Phytocare Limited,
Mumbai.

1. We have reviewed the accompanying statement of Unaudited financial results of **Piramal Phytocare Limited** (Formerly known as Piramal Life Sciences Limited) ("the Company") for the period ended 31st December 2014 ("the Statement"), being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreements with the Stock Exchanges, except for the disclosures in Part – II – Select Information referred to in paragraph 4 below. This statement is the responsibility of the Company's Management and has been approved by the Board of directors / committee of Board of Directors.
2. We have conducted our review in accordance with the Standards on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited financial results prepared in accordance with applicable accounting standards specified under the Companies Act, 1956 (which are deemed to be applicable as per section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. Further, we also report that we have traced the number of shares as well as the percentage of shareholding in respect of the aggregate amount of public shareholding and number of shares as well as the percentage of shares pledged/encumbered and non-encumbered in respect of the aggregate amount of promoters and promoters group shareholding in terms of Clause 35 of the Listing Agreements with the Stock Exchanges and the particulars relating to investor complaints disclosed in Part II – Select Information for the Quarter ended 31st December 2014 of the Statement, from the details furnished by the Registrars.

For Haribhakti & Co.
Chartered Accountant
Firm Reg No: 118013W


Hitesh J. Desai
Partner
M.No.: 037569



Date: 13th February 2015
Place: Mumbai

PIRAMAL PHYTOCARE LIMITED
(Formerly Known As Piramal Life Sciences Limited)
Piramal Tower, Peninsula Corporate Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013.
UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2014

Particulars	(Rs. in Lakhs)					
	3 months ended	preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date for current period ended	Year to date for previous year ended	Previous Year ended
	31/12/2014	30/09/2014	31/12/2013	31/12/2014	31/12/2013	31/03/2014
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Income from operations	158	77	63	341	163	596
Net Sales / Income from Operations	158	77	63	341	163	596
Total Income from Operations (Net)	158	77	63	341	163	596
Expenses						
Cost of Materials Consumed	15	41	-	56	-	-
Purchase of Stock-in-Trade	38	16	25	87	67	-
Changes in inventories of finished goods, work-in-progress and stock-in-trade	14	(24)	-	(10)	-	400
Employee benefits expenses	12	10	13	40	52	66
Depreciation and amortisation expenses	116	115	116	348	347	461
Other Expenses (Net)	36	39	21	112	89	114
Total Expenses	231	197	175	633	555	1041
(Loss) from operations before other income, finance costs and exceptional items	(73)	(120)	(112)	(292)	(392)	(445)
Other Income	7	11	2	27	15	22
(Loss) from ordinary activities before finance costs and exceptional items	(66)	(109)	(110)	(265)	(377)	(423)
Finance Costs	0	0	0	0	0	0
(Loss) from ordinary activities after finance costs but before exceptional items	(66)	(109)	(110)	(265)	(377)	(423)
Exceptional Income (Net)	(66)	(109)	(110)	(265)	(377)	(423)
(Loss) from ordinary activities before tax	(66)	(109)	(110)	(265)	(377)	(423)
Tax Expense	(66)	(109)	(110)	(265)	(377)	(423)
Net (Loss) from ordinary activities after tax	(66)	(109)	(110)	(265)	(377)	(423)
Extraordinary Items (net of tax expense)	-	-	-	-	-	-
Net (Loss) for the period	(66)	(109)	(110)	(265)	(377)	(423)
Paid-up Equity Share Capital (Face Value Rs.10/- each)	2,596	2,596	2,596	2,596	2,596	2,596
Reserves (Excluding Revaluation Reserves)	-	-	-	-	-	(1,423)
Earnings Per Share (EPS)						
a) Basic and diluted EPS before extraordinary items for the period (Rs.) (not annualised)	(0.3)	(0.4)	(0.4)	(1.0)	(1.4)	(1.6)
b) Basic and diluted EPS after extraordinary items for the period (Rs.) (not annualised)	(0.3)	(0.4)	(0.4)	(1.0)	(1.4)	(1.6)

PART II						
A. PARTICULARS OF SHAREHOLDING						
1. Public Shareholding						
- Number of shares	11,023,135	11,023,135	11,023,135	11,023,135	11,023,135	11,023,135
- Percentage of shareholding	42.46%	42.46%	42.46%	42.46%	42.46%	42.46%
2. Promoters and Promoter group Shareholding						
a) Pledged/Encumbered						
- Number of shares	-	-	-	-	-	-
- Percentage of shares (% to total shareholding of promoters and promoter group)	-	-	-	-	-	-
- Percentage of shares (% to the total share capital of the company)	-	-	-	-	-	-
b) Non-encumbered						
- Number of Shares	14,937,205	14,937,205	14,937,205	14,937,205	14,937,205	14,937,205
- Percentage of shares (% to total shareholding of promoters and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (% to the total share capital of the company)	57.54%	57.54%	57.54%	57.54%	57.54%	57.54%

Particulars		3 Months ended
		31/12/2014
B. INVESTOR COMPLAINTS		
Pending at the beginning of the quarter		-
Received during the quarter		-
Disposed of during the quarter		-
Remaining unresolved at the end of the quarter		-



Piramal Phytocare Limited
(formerly known as Piramal Life Sciences Limited)
CIN : L73100MH2001PLC132523


Regd. Office : Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013
Secretarial Dept : Piramal Tower Annexe, 1st floor, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013
T +91 22 3046 7953 / 7839 F +91 22 3046 7855
W www.pls-l.com

Notes:


1. The results for the Quarter and Nine months ended December 31, 2014 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 13, 2015.
2. The Company is engaged in the business of Phytopharmaceuticals which is the primary reportable business segment.
3. The figures for the previous quarter / year have been regrouped / rearranged wherever considered necessary.

For PIRAMAL PHYTOCARE LIMITED
(Formerly known as Piramal Life Sciences Limited)

Mumbai
February 13, 2015



Rajesh Laddha
Director



Piramal Phytocare Limited
[formerly known as Piramal Life Sciences Limited]
CIN : L73100MH2001PLC132523

Regd. Office : Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013
Secretarial Dept : Piramal Tower Annexe, 1st floor, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

T +91 22 3046 7953 / 7839 F +91 22 3046 7855

W www.pls-l.com